家族性乳腺癌风险女性磁共振成像筛查的成本效果
该经济评价采用微观模拟模型,在1000万名具有20%及以上家族性乳腺癌风险且无已知BRCA1/2或TP53变异的荷兰女性中,评估不同MRI筛查策略的终身成本与效果。
要点
- 对于20%及以上家族性乳腺癌风险且无已知BRCA1/2或TP53变异的女性,每18个月一次MRI筛查(35-60岁)具有成本效果。
- 提高成本效果阈值时,每年一次MRI筛查可能更受青睐。
核心结论
- 对于有乳腺癌家族史的女性,35至60岁每18个月一次MRI筛查在所有乳腺密度下均处于NICE阈值内,具有成本效果。
- 更高的阈值将支持每年一次MRI筛查。
研究设计与样本
- 经济评价研究,采用微观模拟模型,时间范围为终身(从25岁至死亡),队列为1000万名具有20%及以上家族性乳腺癌风险且无已知BRCA1/2或TP53变异的荷兰女性。
- 数据主要来自随机FaMRIsc试验(纳入30至55岁荷兰女性),采用医疗卫生支付方视角,成本和效果按3%贴现。
主要发现
- 35至60岁每年交替进行MRI和乳腺X线摄影筛查随后进入国家筛查项目,结果相似。
- ICER对MRI单位成本以及导管原位癌和局限性乳腺癌的效用值最敏感。
临床怎么用
- 对于20%及以上家族性乳腺癌风险且无已知BRCA1/2或TP53变异的女性,可考虑在35至60岁每18个月进行一次MRI筛查,随后进入国家筛查项目。
- 若支付阈值提高,每年一次MRI筛查可能成为更具成本效果的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: For women with a 20% or more familial risk of breast cancer without a known BRCA1/2 (BRCA1, OMIM 113705; and BRCA2, OMIM 114480) or TP53 (OMIM 151623) variant, screening guidelines vary substantially, and cost-effectiveness analyses are scarce. OBJECTIVE: To assess the cost-effectiveness of magnetic resonance imaging (MRI) screening strategies for women with a 20% or more familial risk for breast cancer without a known BRCA1/2 or TP53 variant. DESIGN, SETTING, AND PARTICIPANTS: In this economic evaluation, conducted from February 1, 2019, to May 25, 2020, microsimulation modeling was used to estimate costs and effectiveness on a lifetime horizon from age 25 years until death of MRI screening among a cohort of 10 million Dutch women with a 20% or more familial risk for breast cancer without a known BRCA1/2 or TP53 variant. A Dutch screening setting was modeled. Most data were obtained from the randomized Familial MRI Screening (FaMRIsc) trial, which included Dutch women aged 30 to 55 years. A health care payer perspective was applied. INTERVENTIONS: Several screening protocols with varying ages and intervals including those of the randomized FaMRIsc trial, consisting of the mammography (Mx) protocol (annual mammography and clinical breast examination) and the MRI protocol (annual MRI and clinical breast examination plus biennial mammography). MAIN OUTCOMES AND MEASURES: Costs, life-years, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs) were calculated and discounted by 3%. A threshold of €22 000 (US $24 795.87) per QALY was applied. RESULTS: This economic evaluation modeling study estimated that, on a lifetime horizon per 1000 women with the Mx protocol of the FaMRIsc trial, 346 breast cancers would be detected, and 49 women were estimated to die from breast cancer, resulting in 22 885 QALYs and total costs of €7 084 767 (US $7 985 134.61). The MRI protocol resulted in 79 additional QALYs and additional €2 657 266 (US $2 994 964.65). Magnetic resonance imaging performed only every 18 months between the ages of 35 and 60 years followed by the national screening program was considered optimal, with an ICER of €21 380 (US $24 097.08) compared with the previous nondominated strategy in the ranking, when applying the National Institute for Health and Care Excellence threshold. Annual screening alternating MRI and mammography between the ages of 35 and 60 years, followed by the national screening program, gave similar outcomes. Higher thresholds would favor annual MRI screening. The ICER was most sensitive to the unit cost of MRI and the utility value for ductal carcinoma in situ and localized breast cancer. CONCLUSIONS AND RELEVANCE: This study suggests that MRI screening every 18 months between the ages of 35 and 60 years for women with a family history of breast cancer is cost-effective within the National Institute for Health and Care Excellence threshold for all densities. Higher thresholds would favor annual MRI screening. These outcomes support a change of current screening guidelines for this specific risk group and support MRI screening.
引用
- Geuzinge HA, Obdeijn IM, Rutgers EJT, et al. Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk. JAMA Oncol. 2020. PMID: 32729887. doi:10.1001/jamaoncol.2020.2922
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。